1 January 2016 in Journal of Gynecologic Oncology
Ikeda Y, et al. J Gynecol Oncol. 2015 Dec;27(3):e29. http://dx.doi.org/10.3802/jgo.2016.27.e29
1 April 2019 in Pathology - Research and Practice
20 May 2019 in Journal of Obstetrics and Gynaecology Research
Aim This study aimed to assess adequate conditions for omitting parametrectomy for stage IB1-IIA2 cervical cancer with the aim of reducing postoperative complications during Type III radical hysterectomy (RH). Methods We investigated factors associated with parametrial invasion (PMI) in patients who underwent Type III RH for stage IB1, IB2, IIA1, IIA2 and IIB cervical cancer at two tertiary institutions from November 2006 to February 2018. Both clinicopathological and preoperatively estimated factors were assessed. Results One hundred fifty-six patients were preoperatively diagnosed with stage IB1 to IIB disease. Thirty-four patients (21.8%) showed PMI on histological analyses. In the multivariate analysis, an age older than 50 years, tumor size larger than 40 mm, common iliac lymph node metastasis and lymphovascular space invasion were identified as significant risk factors for PMI (P-values = 0.008, 0.003, 0.004 and 0.004, respectively). The preoperatively estimated risk factors for PMI were an older age, larger tumor size, and common iliac lymph node metastasis (P-values = 0.007, 0.002 and 0.001, respectively). A combination of these three factors was sufficient to estimate PMI with a high specificity (100%) and positive predictive value (100%) in patients with stage IB1 to IIA2 disease. Conclusion During RH, resecting the posterior layer of the vesicouterine ligament and the paracolpium without removing the cardinal ligament (avoiding parametrectomy) might be feasible for stage IB1-IIA2 cervical cancer in patients younger than 50 years presenting with smaller tumors (<40 mm) and no common iliac lymph node metastasis.
1 January 2024 in JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
Objective: The umbilical site is widely used as the initial entry site in laparoscopic surgery. The initial entry procedure may cause organ injury, and thus we use the upper abdominal region as the entry site when umbilical site adhesions are suspected. However, the upper abdominal region is far from the pelvis, and therefore use of this region for the entry site makes pelvic surgery challenging. We investigated which abdominal region, other than the umbilical site, would be suitable for the initial entry. Methods: From January 2020 to December 2022, 181 of the 659 patients who underwent laparoscopic or robot-assisted endoscopic surgery at our hospital had a history of abdominal surgery. The presence of organ adhesion to the abdominal wall (umbilical site [US], left upper abdomen [LU], right upper abdomen [RU], left lower abdomen [LL], right lower abdomen [RL], and the midline of the lower abdomen [ML]) was retrospectively examined. Results: The frequency of organ adhesions at each site was US 23.8%, LU 0.5%, RU 3.9%, LL 4.4%, RL 24.8%, and ML 11.0%. The frequency of organ adhesions in the LL was significantly lower than in the US (p < 0.05). There was no significant difference in the frequency of organ adhesions between the LL and ML. Nevertheless, in the presence of US adhesions, the frequency of organ adhesions was significantly lower in the LL than in the ML (p < 0.05). Conclusion: In patients with a history of abdominal surgery, the left lower abdomen is a safe and appropriate initial entry site.
1 January 2013 in Journal of Clinical Gynecology and Obstetrics
Background: The aim of this retrospective study was to evaluate uterine volume in patients who underwent transabdominal hysterectomy (TAH) or total laparoscopic hysterectomy (TLH) for uterine leiomyomas in our teaching hospital and to determine the appropriate uterine volume in patients who could undergo TLH. Methods: This retrospective study was based on a cohort 47 consecutive cases that underwent TLH for uterine leiomyomas in our institution between April 2008 and April 2012 (TLH group). Controls were defined as 134 patients who underwent TAH for uterine leiomyomas in our institution between April 2008 and April 2012 (TAH group). Results: The TLH group comprised 45 cases because two surgeries in the TLH group were converted to TAH. Uterine volume was significantly smaller in the TLH group than in the TAH group (median 342 g vs. 788 g). Surgical duration was significantly longer in the TLH group than in the TAH group (median 214 minutes vs. 152 minutes). Blood loss was significantly lower in the TLH group than in the TAH group (median 0 mL vs. 250 mL). The incidence of postoperative complications was lower in the TLH group than in the TAH group (0/45 vs. 15/134). The hospital stay was significantly shorter for the TLH group than for the TAH group. In the TLH group, surgical duration correlated with uterine volume (regression coefficient = 1.6598, P = 0.0014). Conclusion: There seems to be no limitation of uterine volume in TLH for uterine leiomyomas because TLH is safer than TAH except for the longer surgical duration. doi: http://dx.doi.org/10.4021/jcgo179w
13 June 2025 in Research Square
Background : Current evidence regarding the prognostic factors of malignant tumors arising from mature cystic teratomas (MT-MCTs) and effective treatments is insufficient. Aim : This study aimed to identify the risk factors for malignant tumors arising from mature cystic teratomas (MT-MCTs) of the ovary. Methods : Tumor samples diagnosed as MT-MCTs were collected from 13 institutions participating in the Kansai Clinical Oncology Group. Based on the clinicopathological features and prognoses of the tumors, the risk factors for progression and death were statistically assessed via univariable and multivariable analyses. Results : Among the 60 tumor samples collected, 56 were diagnosed as MT-MCTs; the exclusion of four samples was based on the results of a central pathological review. Nine histological types, including squamous cell carcinoma, were diagnosed. Thirty of the 56 included samples were classified as International Federation of Gynecology and Obstetrics (FIGO) stage I, seven as FIGO stage II, 18 as FIGO stage III, and one as FIGO stage IV. The 5-year progression-free survival and overall survival rates were significantly higher for stage I disease than for stage II–IV disease (p < 0.001). In the multivariable analysis, surgery with residual tumor margins was a prognostic factor for progression, and FIGO stages I–IV and the absence of adjuvant therapy were prognostic factors for death. Conclusion : Surgery without residual tumor margins followed by adjuvant therapy may be a promising treatment for advanced-stage MT-MCTs.